Sarepta Therapeutics (NASDAQ: SRPT) announced that the Company held a pre-New Drug Application (NDA) meeting with the U.S. Food and ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

WSJ Article Comparing Sarepta (SRPT) and BioMarin (BMRN) 'Juvenile and Uninformed', Roth Capital SaysMay 21, 2015 11:25 AM BofA/Merrill Lynch Downgrades Sarepta Therapeutic (SRPT) to NeutralMay 21, 2015 7:38 AM Sarepta Therapeutic (SRPT) Has 100% Upside, 50% Downside - Deutsche BankMay 20, 2015 1:34 PM Cowen Maintains Neutral View on Sarepta (SRPT) Despite Rolling NDA for EteplirsenMay 20, 2015 9:01 AM Sarepta (SRPT) PT Raised to $25 at Wedbush on Go-Ahead for Eteplirsen NDAMay 20, 2015 7:30 AM Piper Jaffray Remains on Sidelines with Sarepta (SRPT) Despite Rolling NDA For EteplirsenMay 20, 2015 7:08 AM UPDATE: Canaccord Genuity Upgrades Sarepta Therapeutic (SRPT) to BuyMay 20, 2015 6:54 AM SunTrust Upgrades Sarepta Therapeutic (SRPT) to BuyMay 20, 2015 6:53 AM Sarepta Therapeutic (SRPT) PT Raised to $45 at Roth CapitalMay 20, 2015 6:23 AM Sarepta (SRPT) PT Boosted to $34 at Baird Amid Rolling NDA SubmissionMay 20, 2015 6:19 AM